DK1272188T3 - Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer - Google Patents
Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancerInfo
- Publication number
- DK1272188T3 DK1272188T3 DK00973002T DK00973002T DK1272188T3 DK 1272188 T3 DK1272188 T3 DK 1272188T3 DK 00973002 T DK00973002 T DK 00973002T DK 00973002 T DK00973002 T DK 00973002T DK 1272188 T3 DK1272188 T3 DK 1272188T3
- Authority
- DK
- Denmark
- Prior art keywords
- breast cancer
- tyrosine kinase
- treatment
- egfr tyrosine
- kinase inhibitors
- Prior art date
Links
- 229940121647 egfr inhibitor Drugs 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 230000002113 chemopreventative effect Effects 0.000 abstract 1
- 208000030776 invasive breast carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9925958.2A GB9925958D0 (en) | 1999-11-02 | 1999-11-02 | Therapeutic use |
PCT/GB2000/004190 WO2001032155A2 (en) | 1999-11-02 | 2000-11-01 | Use of egfr tyrosine kinase inhibitors for treating breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1272188T3 true DK1272188T3 (da) | 2007-01-29 |
Family
ID=10863835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00973002T DK1272188T3 (da) | 1999-11-02 | 2000-11-01 | Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer |
Country Status (21)
Country | Link |
---|---|
US (1) | US7553815B1 (ko) |
EP (1) | EP1272188B1 (ko) |
JP (1) | JP2003513035A (ko) |
KR (1) | KR100785359B1 (ko) |
CN (1) | CN1197577C (ko) |
AT (1) | ATE339957T1 (ko) |
AU (1) | AU779190B2 (ko) |
BR (1) | BR0015194A (ko) |
CA (1) | CA2389411C (ko) |
CY (1) | CY1106285T1 (ko) |
DE (1) | DE60030889T2 (ko) |
DK (1) | DK1272188T3 (ko) |
ES (1) | ES2275556T3 (ko) |
GB (1) | GB9925958D0 (ko) |
IL (1) | IL149176A0 (ko) |
MX (1) | MXPA02004272A (ko) |
NO (1) | NO323206B1 (ko) |
NZ (1) | NZ518696A (ko) |
PT (1) | PT1272188E (ko) |
WO (1) | WO2001032155A2 (ko) |
ZA (1) | ZA200203431B (ko) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL217410B1 (pl) | 2000-05-19 | 2014-07-31 | Genentech Inc | Zastosowanie antagonisty ErbB, antagonista ErbB do zastosowania w metodzie leczenia raka i sposób identyfikacji pacjenta skłonnego do korzystnej odpowiedzi na antagonistę ErbB przy leczeniu raka |
AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
AU2002349013A1 (en) * | 2001-10-29 | 2003-05-12 | Novartis Ag | Use of 7h-pyrrolo(2,3-d)pyrimidine derivatives in the treatment of solid tumor diseases |
EP1769795B1 (en) * | 2001-12-03 | 2013-07-24 | Bayer HealthCare LLC | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
AU2003238871B2 (en) * | 2002-06-05 | 2009-04-23 | Cedars-Sinai Medical Center | Method of treating cancer using kinase inhibitors |
US20070059785A1 (en) * | 2003-08-15 | 2007-03-15 | Smithkline Beecham Corporation | Biomarkers in cancer |
SI1667992T1 (sl) | 2003-09-19 | 2007-06-30 | Astrazeneca Ab | Kinazolinski derivati |
WO2005039588A2 (en) * | 2003-10-22 | 2005-05-06 | Novartis Ag | Methods for determining the risk of developing liver and lung toxicity |
US7701341B2 (en) * | 2004-09-01 | 2010-04-20 | Microsoft Corporation | Device service provider interface |
CN102580084B (zh) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
SI1850874T1 (sl) | 2005-02-23 | 2014-01-31 | Genentech, Inc. | Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba |
CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
CN101415422B (zh) | 2006-02-09 | 2012-11-07 | 第一三共株式会社 | 抗癌药用组合物 |
CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c-Abl特异性抑制剂的新用途 |
AU2008223069B2 (en) | 2007-03-02 | 2012-12-13 | F. Hoffmann-La Roche Ag | Predicting response to a HER dimerisation inhibitor based on low HER3 expression |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
EP2171090B1 (en) | 2007-06-08 | 2013-04-03 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
CA2972379A1 (en) | 2009-03-11 | 2010-09-16 | Ardea Biosciences, Inc. | Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers |
MY152068A (en) | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
WO2010136569A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
CN102892779B (zh) | 2010-02-18 | 2016-12-21 | 基因泰克公司 | 神经调节蛋白拮抗剂及其在治疗癌症中的用途 |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
CN103890007A (zh) | 2011-08-17 | 2014-06-25 | 霍夫曼-拉罗奇有限公司 | 神经调节蛋白抗体及其用途 |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
SG11201402510TA (en) | 2011-11-30 | 2014-06-27 | Genentech Inc | Erbb3 mutations in cancer |
WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック, インコーポレイテッド | Her3阻害剤に関する診断及び治療 |
MX363188B (es) | 2012-11-30 | 2019-03-13 | Hoffmann La Roche | Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1. |
EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5795910A (en) * | 1994-10-28 | 1998-08-18 | Cor Therapeutics, Inc. | Method and compositions for inhibiting protein kinases |
PT817775E (pt) * | 1995-03-30 | 2002-01-30 | Pfizer | Derivados de quinazolina |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
MX9709867A (es) * | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos. |
PT836605E (pt) * | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
PL348634A1 (en) * | 1998-05-15 | 2002-06-03 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
CN101512597B (zh) | 2006-08-28 | 2013-02-06 | Tp视觉控股有限公司 | 图像增强方法和设备 |
-
1999
- 1999-11-02 GB GBGB9925958.2A patent/GB9925958D0/en not_active Ceased
-
2000
- 2000-11-01 DE DE60030889T patent/DE60030889T2/de not_active Expired - Lifetime
- 2000-11-01 ES ES00973002T patent/ES2275556T3/es not_active Expired - Lifetime
- 2000-11-01 US US10/111,390 patent/US7553815B1/en not_active Expired - Fee Related
- 2000-11-01 MX MXPA02004272A patent/MXPA02004272A/es active IP Right Grant
- 2000-11-01 WO PCT/GB2000/004190 patent/WO2001032155A2/en active IP Right Grant
- 2000-11-01 CA CA002389411A patent/CA2389411C/en not_active Expired - Fee Related
- 2000-11-01 CN CNB00815290XA patent/CN1197577C/zh not_active Expired - Fee Related
- 2000-11-01 BR BR0015194-7A patent/BR0015194A/pt not_active Application Discontinuation
- 2000-11-01 AU AU11559/01A patent/AU779190B2/en not_active Ceased
- 2000-11-01 EP EP00973002A patent/EP1272188B1/en not_active Expired - Lifetime
- 2000-11-01 DK DK00973002T patent/DK1272188T3/da active
- 2000-11-01 IL IL14917600A patent/IL149176A0/xx not_active IP Right Cessation
- 2000-11-01 PT PT00973002T patent/PT1272188E/pt unknown
- 2000-11-01 AT AT00973002T patent/ATE339957T1/de not_active IP Right Cessation
- 2000-11-01 JP JP2001534360A patent/JP2003513035A/ja active Pending
- 2000-11-01 NZ NZ518696A patent/NZ518696A/xx not_active IP Right Cessation
- 2000-11-01 KR KR1020027005551A patent/KR100785359B1/ko not_active IP Right Cessation
-
2002
- 2002-04-30 NO NO20022065A patent/NO323206B1/no not_active IP Right Cessation
- 2002-04-30 ZA ZA200203431A patent/ZA200203431B/xx unknown
-
2006
- 2006-12-11 CY CY20061101772T patent/CY1106285T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001032155A2 (en) | 2001-05-10 |
ES2275556T3 (es) | 2007-06-16 |
NO323206B1 (no) | 2007-01-22 |
DE60030889D1 (de) | 2006-11-02 |
NO20022065D0 (no) | 2002-04-30 |
IL149176A0 (en) | 2002-11-10 |
EP1272188B1 (en) | 2006-09-20 |
WO2001032155A3 (en) | 2002-05-10 |
NZ518696A (en) | 2004-12-24 |
PT1272188E (pt) | 2007-01-31 |
GB9925958D0 (en) | 1999-12-29 |
JP2003513035A (ja) | 2003-04-08 |
BR0015194A (pt) | 2002-06-18 |
CA2389411A1 (en) | 2001-05-10 |
CN1197577C (zh) | 2005-04-20 |
ZA200203431B (en) | 2003-02-26 |
MXPA02004272A (es) | 2003-08-20 |
US7553815B1 (en) | 2009-06-30 |
KR100785359B1 (ko) | 2007-12-18 |
AU1155901A (en) | 2001-05-14 |
CN1387437A (zh) | 2002-12-25 |
KR20020064306A (ko) | 2002-08-07 |
DE60030889T2 (de) | 2007-04-05 |
ATE339957T1 (de) | 2006-10-15 |
AU779190B2 (en) | 2005-01-13 |
NO20022065L (no) | 2002-06-24 |
EP1272188A2 (en) | 2003-01-08 |
CY1106285T1 (el) | 2011-10-12 |
CA2389411C (en) | 2009-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1272188T3 (da) | Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer | |
NZ515567A (en) | Method for treating chronic pain using MEK inhibitors | |
NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
DK1255537T3 (da) | Farnesylproteintransferasehæmmere til behandling af brystcancer | |
IL154949A0 (en) | Imidazole derivatives as raf kinase inhibitors | |
MY138059A (en) | Use of ikb-kinase inhibitors in pain therapy | |
DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
EA200300906A1 (ru) | Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7 | |
TNSN04015A1 (en) | Combination therapy for the treatment of cancer | |
ATE410155T1 (de) | Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung | |
MX2007006927A (es) | Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer. | |
CY1106289T1 (el) | Χρηση αναστολεων υποδοχεος προγεστepονης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου που ειναι ανθεκτικος σε στepοειδη | |
HK1080733A1 (en) | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol | |
TR200101693T2 (tr) | Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi. | |
DE60111515D1 (de) | Kombinationstherapie mit keratinozyten-wachstumfaktor und ein epidermis-wachstumfaktor inhibitor | |
EA200200853A1 (ru) | Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака | |
GEP201606538B (en) | Preoperative treatment of post operative pain | |
NO20024545L (no) | Fremgangsmåte for behandling av kongestiv hjertefeil | |
MXPA03010451A (es) | Nuevos metodos para el tratamiento y prevencion del dolor. | |
UA67528A (en) | Method for surgical treatment of thyroid cancer | |
EA200600987A1 (ru) | Применение сирамезина в лечении злокачественных опухолей | |
ECSP003651A (es) | Nuevos compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas |